Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy
Abstract Chimeric antigen receptor (CAR) engineered cellular immunotherapy offers the potential for precise targeting and elimination of tumor cells, providing a tailored approach to cancer treatment. CAR-T cells demonstrate significant anti-tumor activity among these therapies. Nonetheless, these t...
Saved in:
| Main Authors: | Yong Liu, Yifei Duan, Zefan Du, Bo Lu, Su Liu, Lindi Li, Mengyao Tian, Liang Li, Ran Yao, Cheng Ouyang, Mo Yang, Chun Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-025-00683-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases
by: Mingwei Jiang, et al.
Published: (2025-12-01) -
Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023
by: Wangshu Li, et al.
Published: (2024-12-01) -
Advance in chimeric antigen receptor T therapy in autoimmune diseases
by: Xiaolan Ji, et al.
Published: (2025-03-01) -
Current trends and future of gene-cell immunotherapy in the treatment of HIV infection
by: A. P. Faenko, et al.
Published: (2025-05-01) -
Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors
by: Liaoliao Zhu, et al.
Published: (2025-05-01)